Cargando…

Cysteine catabolism and the serine biosynthesis pathway support pyruvate production during pyruvate kinase knockdown in pancreatic cancer cells

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with limited treatment options. Pyruvate kinase, especially the M2 isoform (PKM2), is highly expressed in PDAC cells, but its role in pancreatic cancer remains controversial. To investigate the role of pyruvate kinase in pan...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Lei, Teoh, Shao Thing, Ensink, Elliot, Ogrodzinski, Martin P., Yang, Che, Vazquez, Ana I., Lunt, Sophia Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937848/
https://www.ncbi.nlm.nih.gov/pubmed/31893043
http://dx.doi.org/10.1186/s40170-019-0205-z
_version_ 1783483949739147264
author Yu, Lei
Teoh, Shao Thing
Ensink, Elliot
Ogrodzinski, Martin P.
Yang, Che
Vazquez, Ana I.
Lunt, Sophia Y.
author_facet Yu, Lei
Teoh, Shao Thing
Ensink, Elliot
Ogrodzinski, Martin P.
Yang, Che
Vazquez, Ana I.
Lunt, Sophia Y.
author_sort Yu, Lei
collection PubMed
description BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with limited treatment options. Pyruvate kinase, especially the M2 isoform (PKM2), is highly expressed in PDAC cells, but its role in pancreatic cancer remains controversial. To investigate the role of pyruvate kinase in pancreatic cancer, we knocked down PKM2 individually as well as both PKM1 and PKM2 concurrently (PKM1/2) in cell lines derived from a Kras(G12D/-); p53(-/-) pancreatic mouse model. METHODS: We used liquid chromatography tandem mass spectrometry (LC-MS/MS) to determine metabolic profiles of wildtype and PKM1/2 knockdown PDAC cells. We further used stable isotope-labeled metabolic precursors and LC-MS/MS to determine metabolic pathways upregulated in PKM1/2 knockdown cells. We then targeted metabolic pathways upregulated in PKM1/2 knockdown cells using CRISPR/Cas9 gene editing technology. RESULTS: PDAC cells are able to proliferate and continue to produce pyruvate despite PKM1/2 knockdown. The serine biosynthesis pathway partially contributed to pyruvate production during PKM1/2 knockdown: knockout of phosphoglycerate dehydrogenase in this pathway decreased pyruvate production from glucose. In addition, cysteine catabolism generated ~ 20% of intracellular pyruvate in PDAC cells. Other potential sources of pyruvate include the sialic acid pathway and catabolism of glutamine, serine, tryptophan, and threonine. However, these sources did not provide significant levels of pyruvate in PKM1/2 knockdown cells. CONCLUSION: PKM1/2 knockdown does not impact the proliferation of pancreatic cancer cells. The serine biosynthesis pathway supports conversion of glucose to pyruvate during pyruvate kinase knockdown. However, direct conversion of serine to pyruvate was not observed during PKM1/2 knockdown. Investigating several alternative sources of pyruvate identified cysteine catabolism for pyruvate production during PKM1/2 knockdown. Surprisingly, we find that a large percentage of intracellular pyruvate comes from cysteine. Our results highlight the ability of PDAC cells to adaptively rewire their metabolic pathways during knockdown of a key metabolic enzyme.
format Online
Article
Text
id pubmed-6937848
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69378482019-12-31 Cysteine catabolism and the serine biosynthesis pathway support pyruvate production during pyruvate kinase knockdown in pancreatic cancer cells Yu, Lei Teoh, Shao Thing Ensink, Elliot Ogrodzinski, Martin P. Yang, Che Vazquez, Ana I. Lunt, Sophia Y. Cancer Metab Research BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with limited treatment options. Pyruvate kinase, especially the M2 isoform (PKM2), is highly expressed in PDAC cells, but its role in pancreatic cancer remains controversial. To investigate the role of pyruvate kinase in pancreatic cancer, we knocked down PKM2 individually as well as both PKM1 and PKM2 concurrently (PKM1/2) in cell lines derived from a Kras(G12D/-); p53(-/-) pancreatic mouse model. METHODS: We used liquid chromatography tandem mass spectrometry (LC-MS/MS) to determine metabolic profiles of wildtype and PKM1/2 knockdown PDAC cells. We further used stable isotope-labeled metabolic precursors and LC-MS/MS to determine metabolic pathways upregulated in PKM1/2 knockdown cells. We then targeted metabolic pathways upregulated in PKM1/2 knockdown cells using CRISPR/Cas9 gene editing technology. RESULTS: PDAC cells are able to proliferate and continue to produce pyruvate despite PKM1/2 knockdown. The serine biosynthesis pathway partially contributed to pyruvate production during PKM1/2 knockdown: knockout of phosphoglycerate dehydrogenase in this pathway decreased pyruvate production from glucose. In addition, cysteine catabolism generated ~ 20% of intracellular pyruvate in PDAC cells. Other potential sources of pyruvate include the sialic acid pathway and catabolism of glutamine, serine, tryptophan, and threonine. However, these sources did not provide significant levels of pyruvate in PKM1/2 knockdown cells. CONCLUSION: PKM1/2 knockdown does not impact the proliferation of pancreatic cancer cells. The serine biosynthesis pathway supports conversion of glucose to pyruvate during pyruvate kinase knockdown. However, direct conversion of serine to pyruvate was not observed during PKM1/2 knockdown. Investigating several alternative sources of pyruvate identified cysteine catabolism for pyruvate production during PKM1/2 knockdown. Surprisingly, we find that a large percentage of intracellular pyruvate comes from cysteine. Our results highlight the ability of PDAC cells to adaptively rewire their metabolic pathways during knockdown of a key metabolic enzyme. BioMed Central 2019-12-30 /pmc/articles/PMC6937848/ /pubmed/31893043 http://dx.doi.org/10.1186/s40170-019-0205-z Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Yu, Lei
Teoh, Shao Thing
Ensink, Elliot
Ogrodzinski, Martin P.
Yang, Che
Vazquez, Ana I.
Lunt, Sophia Y.
Cysteine catabolism and the serine biosynthesis pathway support pyruvate production during pyruvate kinase knockdown in pancreatic cancer cells
title Cysteine catabolism and the serine biosynthesis pathway support pyruvate production during pyruvate kinase knockdown in pancreatic cancer cells
title_full Cysteine catabolism and the serine biosynthesis pathway support pyruvate production during pyruvate kinase knockdown in pancreatic cancer cells
title_fullStr Cysteine catabolism and the serine biosynthesis pathway support pyruvate production during pyruvate kinase knockdown in pancreatic cancer cells
title_full_unstemmed Cysteine catabolism and the serine biosynthesis pathway support pyruvate production during pyruvate kinase knockdown in pancreatic cancer cells
title_short Cysteine catabolism and the serine biosynthesis pathway support pyruvate production during pyruvate kinase knockdown in pancreatic cancer cells
title_sort cysteine catabolism and the serine biosynthesis pathway support pyruvate production during pyruvate kinase knockdown in pancreatic cancer cells
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937848/
https://www.ncbi.nlm.nih.gov/pubmed/31893043
http://dx.doi.org/10.1186/s40170-019-0205-z
work_keys_str_mv AT yulei cysteinecatabolismandtheserinebiosynthesispathwaysupportpyruvateproductionduringpyruvatekinaseknockdowninpancreaticcancercells
AT teohshaothing cysteinecatabolismandtheserinebiosynthesispathwaysupportpyruvateproductionduringpyruvatekinaseknockdowninpancreaticcancercells
AT ensinkelliot cysteinecatabolismandtheserinebiosynthesispathwaysupportpyruvateproductionduringpyruvatekinaseknockdowninpancreaticcancercells
AT ogrodzinskimartinp cysteinecatabolismandtheserinebiosynthesispathwaysupportpyruvateproductionduringpyruvatekinaseknockdowninpancreaticcancercells
AT yangche cysteinecatabolismandtheserinebiosynthesispathwaysupportpyruvateproductionduringpyruvatekinaseknockdowninpancreaticcancercells
AT vazquezanai cysteinecatabolismandtheserinebiosynthesispathwaysupportpyruvateproductionduringpyruvatekinaseknockdowninpancreaticcancercells
AT luntsophiay cysteinecatabolismandtheserinebiosynthesispathwaysupportpyruvateproductionduringpyruvatekinaseknockdowninpancreaticcancercells